New combo therapy shows promise for Hard-to-Treat bile duct cancer
NCT ID NCT07364305
First seen Jan 26, 2026 · Last updated May 03, 2026 · Updated 15 times
Summary
This study tests a treatment for people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. The treatment combines chemotherapy delivered directly to the liver (HAIC) with immunotherapy drugs. The goal is to shrink tumors enough to allow surgery and to improve survival. About 50 adults with this cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Eastern Hepatobiliary Surgery Hospital
RECRUITINGShanghai, Shanghai Municipality, 200438, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.